Virios Therapeutics, Inc.
Virios Therapeutics, Inc. (VIRI) Stock Overview
Explore Virios Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
VIRI Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Virios Therapeutics, Inc. (VIRI) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $3.22.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.00 and a market capitalization of 206.5K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.
Mr. Gregory Duncan
4
44 Milton Avenue, Alpharetta, GA
2020